

REPORT TO THE LEGISLATURE
Pursuant to P.A. 87 of 2021
Section 807
Hepatitis C Treatment Report
4th Qtr-FY22

Section 807: The funds appropriated in part 1 for Hepatitis C treatment shall be used only to purchase specialty medication for Hepatitis C treatment in the prison population. In addition to the above appropriation, any rebates received from the medications used shall be used only to purchase specialty medication for Hepatitis C treatment. On a quarterly basis, the department shall issue a report to the senate and house appropriations subcommittees on corrections, the senate and house fiscal agencies, and the legislative corrections ombudsman, showing for the previous 4 quarters the total amount spent on specialty medication for the treatment of Hepatitis C, the number of prisoners that were treated, the amount of any rebates that were received from the purchase of specialty medication, and what outstanding rebates are expected to be received.

QTR	# of Prisoners that started treatment during QTR	Total # of prisoners in Treatment during QTR	# of Prisoners that completed treatment during QTR	Total expenditures during QTR	Total rebate rec'd	Total rebate expected
1st QTR FY 2022	138	279	159	\$ 2,333,698	\$ 27,133	\$ 26,475
2nd QTR FY 2022	184	300	149	\$ 2,604,953	\$ 17,475	\$ 25,213
3rd QTR FY 2022	125	264	175	\$ 2,148,450	\$ -	\$ 28,142
4th QTR FY 2022	118	207	105	\$ 1,800,677	\$ -	\$ 21,263